Bayer Will Continue To Develop Repinotan Despite Cutting Stroke Research
Bayer plans to continue Phase III development of stroke drug repinotan despite terminating research on other stroke candidates.
Bayer plans to continue Phase III development of stroke drug repinotan despite terminating research on other stroke candidates.